Regulation of Interleukin-6 and Leptin in Schizophrenia Patients: A Preliminary Analysis

키워드

참고문헌 (59)

1. Watanabe Y, "Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models", Psychiatry Clin Neurosci, 64, pp.217~230 (2010)
2. Irish Schizophrenia Genomics Consortium and the Wellcome Trust Case Control Consortium 2, "Genome-wide association study implicates HLA-C*01:02 as a risk factor at the major histocompatibility complex locus in schizophrenia", Biol Psychiatry, 72, pp.620~628 (2012)
3. Walker E, "Schizophrenia:etiology and course", Annu Rev Psychol, 55, pp.401~430 (2004)
4. Tsuang MT, "Genes, environment and schizophrenia", Br J Psychiatry Suppl, 40, pp.s18~s24 (2001)
5. Gabay C., "Interleukin-6 and chronic inflammation", Arthritis Res Ther, 8(Suppl 2), pp.S3~ (2006)
6. Doorduin J, "Neuroinflammation in schizophrenia-related psychosis: a PET study", J Nucl Med, 50, pp.1801~1807 (2009)
7. Monji A, "Cytokines and schizophrenia:Microglia hypothesis of schizophrenia", Psychiatry Clin Neurosci, 63, pp.257~265 (2009)
8. Gabay C, "Acute-phase proteins and other systemic responses to inflammation", N Engl J Med, 340, pp.448~454 (1999)
9. Zakharyan R, "Inflammatory cytokine network in schizophrenia", World J Biol Psychiatry, 15, pp.174~187 (2014)
10. Lord GM., "Leptin as a proinflammatory cytokine", Contrib Nephro, 151, pp.151~164 (2006)
11. Sentissi O, "Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review", Schizophr Bull, 34, pp.1189~1199 (2008)
12. Fantuzzi G, "Leptin in the regulation of immunity, inflammation, and hematopoiesis", J Leukoc Biol, 68, pp.437~446 (2000)
13. Faggioni R, "Leptin regulation of the immune response and the immunodeficiency of malnutrition", FASEB J, 15, pp.2565~2571 (2001)
14. Matarese G, "Leptin in immunology", J Immunol, 174, pp.3137~3142 (2005)
15. Li J, "Inflammation and leptin", Drug Discov Today: Dis Mech, 3, pp.387~393 (2006)
16. Wisse BE., "The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity", J Am Soc Nephrol, 15, pp.2792~2800 (2004)
17. Pollmächer T., "Brain somatic cross-talk and the central control of metabolism", pp.143~153 (2003), Springer
18. DiLeone RJ., "The influence of leptin on the dopamine system and implications for ingestive behavior", Int J Obes (Lond), 33(Suppl 2), pp.S25~S29 (2009)
19. Moulin CM, "Impact of adiposity on immunological parameters", Arq Bras Endocrinol Metabol, 53, pp.183~189 (2009)
20. Makki K, "Adipose tissue in obesityrelated inflammation and insulin resistance: cells, cytokines, and chemokines", ISRN Inflamm, 2013, pp.139239~ (2013)
21. Klok MD, "The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review", Obes Rev, 8, pp.21~34 (2007)
22. Martí A, "Obesity and immune function relationships", Obes Rev, 2, pp.131~140 (2001)
23. Calle EE, "Overweight, obesity and cancer:epidemiological evidence and proposed mechanisms", Nat Rev Cancer, 4, pp.579~591 (2004)
24. Esser N, "Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes", Diabetes Res Clin Pract, 105, pp.141~150 (2014)
25. Falagas ME, "Obesity and infection", Lancet Infect Dis, 6, pp.438~446 (2006)
26. Trujillo ME, "Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro", J Clin Endocrinol Metab, 89, pp.5577~5582 (2004)
27. Bruun JM, "Effects of pro-inflammatory cytokines and chemokines on leptin production in human adipose tissue in vitro", Mol Cell Endocrinol, 190, pp.91~99 (2002)
28. Granowitz EV., "Transforming growth factor-beta enhances and pro-inflammatory cytokines inhibit ob gene expression in 3T3-L1 adipocytes", Biochem Biophys Res Commun, 240, pp.382~385 (1997)
29. Kay SR, "The positive and negative syndrome scale (PANSS) for schizophrenia", Schizophr Bull, 13, pp.261~276 (1987)
30. Davis JM., "Dose equivalence of the antipsychotic drugs", J Psychiatr Res, 11, pp.65~69 (1974)
31. Woods SW., "Chlorpromazine equivalent doses for the newer atypical antipsychotics", J Clin Psychiatry, 64, pp.663~667 (2003)
32. Wei J, "Increase of plasma IL-6 concentration with age in healthy subjects", Life Sci, 51, pp.1953~1956 (1992)
33. Ganguli R, "Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness", Psychiatry Res, 51, pp.1~10 (1994)
34. Haack M, "Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis", J Psychiatr Res, 33, pp.407~418 (1999)
35. Akiyama K., "Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration", Schizophr Res, 37, pp.97~106 (1999)
36. Dunjic-Kostic B, "Serum levels of interleukin-6 and tumor necrosis factor-alpha in exacerbation and remission phase of schizophrenia", Psychiatr Danub, 25, pp.55~61 (2013)
37. Frommberger UH, "Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission", Eur Arch Psychiatry Clin Neurosci, 247, pp.228~233 (1997)
38. Kunz M, "Serum levels of IL-6, IL-10 and TNF-αin patients with bipolar disorder and schizophrenia:differences in pro- and anti-inflammatory balance", Rev Bras Psiquiatr, 33, pp.268~274 (2011)
39. Maes M, "Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine", Acta Psychiatr Scand, 89, pp.346~351 (1994)
40. Schmitt A, "Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication", Neuropsychiatr Dis Treat, 1, pp.171~177 (2005)
41. Greenberg AS, "Obesity and the role of adipose tissue in inflammation and metabolism", Am J Clin Nutr, 83, pp.461~465 (2006)
42. Fantuzzi G., "Adipose tissue, adipokines, and inflammation", J Allergy Clin Immunol, 115, pp.911~919 (2005)
43. Aronson D, "Factor analysis of risk variables associated with low-grade inflammation", Atherosclerosis, 200, pp.206~212 (2008)
44. Gispen-de Wied CC., "Stress in schizophrenia: an integrative view", Eur J Pharmacol, 405, pp.375~384 (2000)
45. Kiecolt-Glaser JK., "Stress, food, and inflammation: psychoneuroimmunology and nutrition at the cutting edge", Psychosom Med, 72, pp.365~369 (2010)
46. Berg AH, "Adipose tissue, inflammation, and cardiovascular disease", Circ Res, 96, pp.939~949 (2005)
47. Kluge M, "Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever", Psychoneuroendocrinology, 34, pp.118~128 (2009)
48. Maes M, "In vivo immunomodulatory effects of clozapine in schizophrenia", Schizophr Res, 26, pp.221~225 (1997)
49. Lü LX, "Effect of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia", Di Yi Jun Yi Da Xue Xue Bao, 24, pp.1251~1254 (2004)
50. Pae CU, "Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines", Int Immunopharmacol, 6, pp.666~671 (2006)
51. Kim YK, "Cytokine changes and tryptophan metabolites in medication-naïve and medication-free schizophrenic patients", Neuropsychobiology, 59, pp.123~129 (2009)
52. Lin CC, "Increased interleukin-6 level in Taiwanese schizophrenic patients", Chang Gung Med J, 34, pp.375~381 (2011)
53. Maes M, "Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics", Eur Neuropsychopharmacol, 10, pp.119~124 (2000)
54. Jin H, "Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin", Schizophr Res, 100, pp.70~85 (2008)
55. Dodd S, "Putative neuroprotective agents in neuropsychiatric disorders", Prog Neuropsychopharmacol Biol Psychiatry, 42, pp.135~145 (2013)
56. Davis C, "Neuroprotective effects of leptin in the context of obesity and metabolic disorders", Neurobiol Dis (2014)[DOI]
57. Tourjman V, "Immunomodulatory effects of antipsychotics on inflammatory mediators: a review", Adv Biosci Biotechnol, 3, pp.551~565 (2012)
58. Murashita M, "Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia", Psychiatry Clin Neurosci, 61, pp.54~58 (2007)
59. Beumer W, "Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome", Psychoneuroendocrinology, 37, pp.1901~1911 (2012)

관련 논문AI추천